{"acquisitions":[],"changes":[{"companyHref":"/c/newlimit-com","date":"2026-09-30","documentUrl":"https://www.8vc.com/companies","domain":"newlimit.com","fact":"provenance:investor:8vc","name":"NewLimit","new":{"publisher":"8VC","status":"sourced","url":"https://www.8vc.com/companies"},"old":{"publisher":null,"status":"unknown","url":null},"publisher":"8VC","reason":null,"retrievedAt":"2026-09-30","slug":"newlimit-com","status":"sourced","url":"https://whoraisedwhat.com/c/newlimit-com"}],"country":"US","description":"NewLimit is a biotechnology company developing medicines that restore youthful function to old cells by reprogramming the epigenome. It targets patients with age-related diseases of the liver, immune, and vascular systems. Rather than altering DNA, it reverses cellular aging through epigenetic reprogramming guided by single-cell genomics.","domain":"newlimit.com","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":["8vc"],"lat":37.65354,"lng":-122.416866,"location":"South San Francisco, United States","multiples":[],"name":"NewLimit","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":130000000,"connectionsAmong":[],"currency":"USD","date":"2025-05-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"newlimit-com-2025-05-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-07","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"newlimit-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-07","status":"attributed","url":null},{"fact":"existence","publisher":"newlimit.com","retrievedAt":"2026-06-07","status":"self-reported","url":"https://newlimit.com"},{"fact":"description","publisher":"newlimit.com","retrievedAt":"2026-06-07","status":"self-reported","url":"https://newlimit.com"},{"fact":"investor:8vc","publisher":"8VC","retrievedAt":"2026-09-30","status":"sourced","url":"https://www.8vc.com/companies"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[{"id":"investor:{\"actorKind\": \"investor\", \"name\": \"8VC\", \"role\": \"portfolio\", \"slug\": \"8vc\", \"sources\": [{\"publisher\": \"8VC\", \"retrievedAt\": \"2026-09-30\", \"status\": \"sourced\", \"url\": \"https://www.8vc.com/companies\"}]}","kind":"investor","sources":[{"publisher":"8VC","retrievedAt":"2026-09-30","status":"sourced","url":"https://www.8vc.com/companies"}],"text":"NewLimit was listed in 8VC's portfolio, recorded 2026-09-30."}],"generatedAt":"2026-11-09","investors":[{"actorKind":"investor","name":"8VC","role":"portfolio","slug":"8vc","sources":[{"publisher":"8VC","retrievedAt":"2026-09-30","status":"sourced","url":"https://www.8vc.com/companies"}]}],"state":"insufficient-evidence","tldr":[]},"techStack":["cloudflare","doubleclick floodlight","google font api","google hosted libraries","hsts","http/3","jquery 3.5.1","mysql","php","vercel speed insights","wordpress"],"totalRaisedUsd":347000000,"traction":[],"updatedAt":"2026-06-07","valuations":[]}